Uterine Fibroids Clinical Trials

A listing of Uterine Fibroids medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Languages supported at study center
Age Group

Male only (9)
Female only (25)
Any (203)

Phase 1 (23)
Phase 1/2 (11)
Phase 2 (31)
Phase 2/3 (5)
Phase 3 (20)
Phase 4 (6)
Unknown (141)

Interventional (137)
Observational (94)

Sanofi (22)
Genzyme, a Sanofi Company (14)
Dana-Farber Cancer Institute (6)
Sanofi Pasteur, a Sanofi Company (6)
National Cancer Institute (NCI) (5)
AstraZeneca (3)
University of Medicine and Pharmacy at Ho Chi Minh City (3)
University of Milano Bicocca (3)
Wake Forest University Health Sciences (3)
Hospices Civils de Lyon (2)
IRCCS Eugenio Medea (2)
Imperial College London (2)
Istituto Clinico Humanitas (2)
Manuel Monreal (2)
Massachusetts General Hospital (2)
National Cancer Institute, Naples (2)
National Institute of Neurological Disorders and Stroke (NINDS) (2)
Region Halland (2)
Topadur Pharma AG (2)
Universitair Ziekenhuis Brussel (2)
University Hospital Inselspital, Berne (2)
University Hospital, Angers (2)
Uppsala University (2)
AbbVie (1)
Ain Shams University (1)
Alexandria University (1)
Ascentage Pharma Group Inc. (1)
Asociacion para el Estudio de las Enfermedades Infecciosas (1)
Assistance Publique Hopitaux De Marseille (1)
Aveiro University (1)
Balgrist University Hospital (1)
Bassett Healthcare (1)
Baylor College of Medicine (1)
Baylor Research Institute (1)
Big Ten Cancer Research Consortium (1)
BioNTech RNA Pharmaceuticals GmbH (1)
Boryung Pharmaceutical Co., Ltd (1)
Boston Children's Hospital (1)
Carmel Medical Center (1)
Case Comprehensive Cancer Center (1)
Celgene (1)
Centre Georges Francois Leclerc (1)
Centre Hospitalier Intercommunal Creteil (1)
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (1)
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (1)
Centre Hospitalier Sud Francilien (1)
Centre Hospitalier Universitaire Dijon (1)
Centre Hospitalier Universitaire de Nīmes (1)
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1)
Charles University, Czech Republic (1)
Children's Hospital Medical Center, Cincinnati (1)
Children's Oncology Group (1)
Chinese Medical Association (1)
Chinese PLA General Hospital (1)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1)
Collège des Pneumologues des Hôpitaux Généraux (1)
Copenhagen University Hospital, Hvidovre (1)
David Avigan (1)
Dermata Therapeutics (1)
ESSA Pharmaceuticals (1)
Erebouni Medical Center (1)
Folktandvården Stockholms län AB (1)
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)
Fundacion Clinic per a la Recerca Biomédica (1)
Fundacion GenesisCare (1)
Gilead Sciences (1)
Grupo Espanol de Investigacion en Sarcomas (1)
Gustave Roussy, Cancer Campus, Grand Paris (1)
Haim Bio Co., Ltd. (1)
Hasselt University (1)
Hellenic Society of Medical Oncology (1)
Herlev Hospital (1)
HidraMed Solutions Ltd (1)
Hoffmann-La Roche (1)
Holterman, Ai-Xuan, M.D. (1)
Hospital Vall d'Hebron (1)
Hull University Teaching Hospitals NHS Trust (1)
I.M. Sechenov First Moscow State Medical University (1)
IRCCS Fondazione Stella Maris (1)
Indiana University (1)
Institut Cancerologie de l'Ouest (1)
Institut Jean-Godinot (1)
Institut National de la Santé Et de la Recherche Médicale, France (1)
Institut Pasteur (1)
Institut du Cancer de Montpellier - Val d'Aurelle (1)
Instituto de Investigación Hospital Universitario La Paz (1)
Istituto Ortopedico Rizzoli (1)
Italian Association Neuroendocrine Tumors (1)
James Cleary, MD, PhD (1)
Joslin Diabetes Center (1)
Karolinska Institutet (1)
King's College London (1)
Klinikum-Fuerth (1)
Mahidol University (1)
Marcela V. Maus, M.D.,Ph.D. (1)
Marianne Andersen (1)
Martini-Klinik am UKE GmbH (1)
Methodist Health System (1)
Montefiore Medical Center (1)

No (188)
Yes (49)

No (233)
Yes (4)

Armenian (4)
Argentinian Spanish (3)
Asturian (3)
Australian English (2)
Albanian (1)
Arabic (1)
Bengali (1)
British English (1)
English (1)
Hindi (1)

Adult (18+) (216)
Pediatric (Under 18) (71)

I am/have/had

I am/have/hadcancer

I am/have/hadhysterectomy

I am/have/hadHIV Infection

I am/have/hadhepatitis b

I am/have/hadplatelet count

I am/have/hadchronic kidney disease

I am/have/hadbody mass index

I am/have/hadMRI

I am/have/hadinfertility

I am/have/hadct scan

I am/have/hadprogesterone

I am/have/hadbreast cancer

I am/have/hadglomerular filtration rate

I am/have/hadprimary tumor

I am/have/hadpancreatic cancer

I am/have/hadSARS

I am/have/hadshock

I am/have/hadanticoagulants

I am/have/hadblood transfusion

I am/have/hadabsolute neutrophil count

added new label for I am/have/had

I am looking for

I am looking forhepatitis b

I am looking fordexamethasone

I am looking forantral

I am looking forinsulin

I am looking forprogesterone

I am looking foranesthesia

I am looking forexperimental drug

I am looking forletrozole

I am looking forgoserelin

I am looking forhormone therapy

I am looking formonoclonal antibodies

I am looking forinfluenza

I am looking foratezolizumab

I am looking forimmune checkpoint inhibitor

I am looking formeningococcal

I am looking forhib vaccine

I am looking forarginine

I am looking forbisphosphonate

I am looking forantibiotic

I am looking foranticoagulants

added new label for I am looking for

Advanced Filters

Found 589 clinical trials

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

gemcitabine

pdac

pancreatic cancer

platelet count

cancer chemotherapy

0 views
24 Nov, 2025
1 location

For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors

The goal of this proposal is to test the overall hypothesis that e-cigarettes (ECs) provide efficient nicotine delivery to the brain and arterial blood in non-EC-nave smokers and e-cigarette users and that EC liquid characteristics modulate this effect. This study will test the hypothesis through complementary methods that include [ …

0 views
19 Feb, 2024
1 location

Multi-country trial
Phase 2
For pediatric ages
For adults
Recruiting in 10s
Interventional Study
For Males
Genetic Disease
Recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective:

<ul>

To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

ul>

Secondary Objective:

<ul>

To characterize the safety and tolerability

To characterize the pharmacokinetics (PK)

ul>

fitusiran

factor ix

antihemophilic factor

hemophilia

bethesda assay

0 views
19 Feb, 2024
11 locations

Multi-country trial
Phase 2
For pediatric ages
For adults
Recruiting in 10s
Interventional Study
For Males
Genetic Disease
Recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective:

<ul>

To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

ul>

Secondary Objective:

<ul>

To characterize the safety and tolerability

To characterize the pharmacokinetics (PK)

ul>

fitusiran

factor ix

antihemophilic factor

hemophilia

bethesda assay

0 views
19 Feb, 2024
11 locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives:

<ul>

To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)

To evaluate the pharmacokinetics (PK) of SC and IV isatuximab

ul>

Secondary Objectives:

<ul>

To estimate absolute bioavailability of SC and IV isatuximab

To measure receptor occupancy (RO) after isatuximab SC versus IV …

hepatitis

refractory multiple myeloma

corticosteroids

pomalidomide

isatuximab

0 views
24 Nov, 2025
14 locations

Multi-country trial
Phase 2
For adults
Recruiting in 10s
Interventional Study
all
Cardiovascular Diseases
Recruiting

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

ul>

0 views
19 Feb, 2024
23 locations

Multi-country trial
Includes pre-screening
Phase 2
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

ul>

0 views
01 Dec, 2025
20 locations

Multi-country trial
Phase 2
For pediatric ages
For Seniors
Recruiting in 10s
Interventional Study
all
Recruiting

Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

ul>

0 views
19 Feb, 2024
7 locations

Multi-country trial
Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Family Medicine
Recruiting

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives:

<ul>

Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)

Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when …

bone marrow plasma cells

dexamethasone

multiple myeloma

residual tumor

minimal residual disease

0 views
24 Nov, 2025
16 locations

Multi-country trial
Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Family Medicine
Recruiting

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives:

<ul>

Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)

Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared …

bone marrow plasma cells

dexamethasone

multiple myeloma

residual tumor

minimal residual disease

0 views
24 Nov, 2025
16 locations